



(51) International Patent Classification:

C07C 311/51 (2006.01) A61K 31/44 (2006.01)
 C07D 207/08 (2006.01) A61K 31/445 (2006.01)
 C07D 213/82 (2006.01) A61K 31/18 (2006.01)
 C07D 307/12 (2006.01) A61P 25/04 (2006.01)

(21) International Application Number:

PCT/US2013/042111

(22) International Filing Date:

21 May 2013 (21.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2012/001324 22 May 2012 (22.05.2012) IB
 61/650,934 23 May 2012 (23.05.2012) US
 61/785,601 14 March 2013 (14.03.2013) US

(71) Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). XENON PHARMACEUTICALS INC. [CA/CA]; 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(72) Inventors; and

(71) Applicants : ANDREZ, Jean-Christophe [FR/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). CHOWDHURY, Sultan [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). DECKER, Shannon [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). DEHNHARDT, Christoph, Martin [US/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). FOCKEN, Thilo [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). GRIMWOOD, Michael, Edward [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). HEMEON, Ivan, William [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). JIA, Qi [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). LI, Jun [CN/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). ORTWINE,

Daniel, F. [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). SAFINA, Brian [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). SHENG, Tao [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). SUN, Shaoyi [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). SUTHERLIN, Daniel, P. [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). WILSON, Michael, Scott [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA). ZENOVA, Alla, Yurevna [CA/CA]; c/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(74) Agents: HARRIS, Robert, J. et al.; Viksnins Harris & Pady PLLP, 7900 International Drive, Suite 670, Bloomington, Minnesota 55425 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

(54) Title: N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN



(57) Abstract: The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables R^A , subscript n , ring A , X^2 , L , subscript m , X^1 , B , R^1 , R^2 , R^3 , R^4 , R^5 and R^N have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

